Medpace Holdings, Inc. (NASDAQ:MEDP) Receives $467.08 Consensus Target Price from Brokerages

Medpace Holdings, Inc. (NASDAQ:MEDP) has been assigned an average rating of “Hold” from the fifteen analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ten have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $467.0833.

Several equities research analysts have weighed in on MEDP shares. Barclays cut their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. BMO Capital Markets cut their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Robert W. Baird cut their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th.

Medpace Trading Up 1.4%

NASDAQ:MEDP opened at $519.96 on Friday. Medpace has a 12 month low of $305.69 and a 12 month high of $628.92. The firm has a fifty day simple moving average of $451.02 and a 200-day simple moving average of $496.81. The company has a market capitalization of $14.85 billion, a P/E ratio of 32.68, a PEG ratio of 2.60 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm’s quarterly revenue was up 26.5% on a year-over-year basis. During the same period in the previous year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts forecast that Medpace will post 17.04 EPS for the current year.

Insiders Place Their Bets

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Medpace

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MEDP. Optiver Holding B.V. acquired a new position in shares of Medpace in the third quarter worth about $27,000. Geneos Wealth Management Inc. raised its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. acquired a new position in shares of Medpace in the fourth quarter worth about $30,000. Elyxium Wealth LLC acquired a new position in shares of Medpace in the fourth quarter worth about $30,000. Finally, Basecamp Wealth Advisors LLC raised its position in shares of Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after acquiring an additional 45 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.